^
Association details:
| Biomarker: | FGFR4 deletion |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Excerpt:
In contrast, loss of FGF19 or its receptor FGFR4 led to a remarkable increase in sorafenib-induced ROS generation and apoptosis. In addition, knockdown of FGF19 in sorafenib-resistant HCC cells significantly enhanced the sensitivity to sorafenib.
DOI:
10.1186/s13046-016-0478-9
